Table 4 Sensitivity and positive predictive value (PPV), with 95% confidence interval (95%CI), of triage strategies for high-grade cervical abnormalities among women living with HIV who tested HPV positive on the provider-collected (Provider) or self-collected (Self) specimen for women living with HIV. Sensitivity was calculated for all endpoints diagnosed, not just among HPV-positive women. N+, number of positives by that triage strategy; N_HG, number of high-grade cervical abnormalities interpretation who tested positive by that triage strategy

HPV+

223

47

95.9%

86.0–99.5%

20.7%

15.2–25.9%

257

45

91.8%

80.4–97.7%

17.5%

13.1–22.7%

HPV16+

47

18

36.7%

23.4–51.7%

38.3%

24.5–53.6%

57

17

34.7%

21.7–49.6%

29.8%

18.4–43.4%

HPV16/18/45+

95

30

61.2%

46.2–74.8%

31.6%

22.4–41.9%

118

29

59.2%

44.2–73.0%

24.6%

17.1–33.4%

VIA+

56

21

42.9%

28.8–57.8%

37.5%

24.9–51.5%

54

20

38.8%

25.2–53.8%

37.0%

24.3–51.3%

HPV16+ and VIA+

16

10

20.4%

10.2–34.3%

62.5%

35.4–84.8%

14

9

18.4%

8.8–32.0%

64.3%

35.4–87.2%

HPV16/18/45+ and VIA+

27

15

30.6%

18.3–45.4%

55.6%

35.3–74.5%

28

15

30.6%

18.3–45.4%

53.6%

33.9–72.5%

HPV16+ or VIA+

87

29

59.2%

44.2–73.0%

33.3%

23.6–44.3%

97

28

57.1%

42.2–71.2%

28.9%

20.1–39.0%

HPV16/18/45+ or VIA+

124

36

73.5%

58.9–85.1%

29.0%

21.2–37.9%

144

34

69.4%

54.6–81.7%

23.6%

16.9–31.4%